National Headache Foundation Survey Shows Majority of People with Migraine are Unable to Control Disease and Dissatisfied with Current Preventive Treatment Options
- 84% of people currently taking a preventive treatment wish there was a better treatment option
- Migraine disease has a broad and negative impact, affecting people s socio-emotional health and their family, professional and social lives
- More than two-thirds (67%) of people with migraine who have tried or are currently taking a preventive treatment feel like they are chasing an unreachable goal to get their migraine disease under control
News provided by
Share this article
Share this article
CHICAGO, May 11, 2021 /PRNewswire/ The National Headache Foundation today announced findings from a new survey,
NEW HAVEN, Conn., May 10, 2021 /PRNewswire/ Â Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the Company ), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases including rare disorders, today reported financial results for the first quarter ended March 31, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones.
Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, NURTEC ODT s performance, with its differentiated efficacy and safety profile, continues to be bolstered by overwhelmingly positive patient and provider sentiment to date. We are highly encouraged by the continued success of NURTEC ODT, with net revenues of $43.8 million in the first quarter exceeding expectations.
Biohaven Reports First Quarter 2021 Financial Results and Recent Business Developments
- Exceeded expectations of NURTEC™ ODT (rimegepant) with net product revenue of $43.8 million for the first quarter of 2021, totaling $107.4 million in net product revenue since launch in March 2020
- Continued brand momentum for NURTEC ODT totaling more than 600,000 prescriptions from product launch to date, with more than 33,000 unique prescribers
- Advanced Neuroinnovation™ Platform with multiple Phase 3 studies results expected within the next year, and enrolled first patient in Phase 2/3 trial of oral zavegepant, prompting $100 million Royalty Pharma milestone payment
News provided by
Share this article
Share this article
As a result of an inadvertent error, the version of the earnings release Biohaven Pharmaceutical Holding Company Ltd. ( Biohaven ) issued before market open on May 10, 2021 (the Original Earnings Release ) included certain inaccurate financial and operational data
Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results
Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated. “Coming off an R&D Day last week, we are very excited to have launched a new chapter in Trillium’s …
Trillium Therapeutics Inc. (NASDAQTSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated.